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Abstract
Background—Increases in illicit pharmaceutical opioid (PO) use have been associated with risk 
for transition to heroin use. We identify predictors of transition to heroin use among young, illicit 
PO users with no history of opioid dependence or heroin use at baseline.
Methods—Respondent-driven sampling recruited 383 participants; 362 returned for at least one 
biannual structured interview over 36 months. Cox regression was used to test for associations 
between lagged predictors and hazard of transition to heroin use. Potential predictors were based 
on those suggested in the literature. We also computed population attributable risk (PAR) and the 
rate of heroin transition.
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Results—Over 36 months, 27 (7.5%) participants initiated heroin use; all were white, and the 
rate of heroin initiation was 2.8% per year (95% CI=1.9%–4.1%). Mean length of PO at first 
reported heroin use was 6.2 years (SD=1.9). Lifetime PO dependence (AHR=2.39, 95% CI= 1.07–
5.48; PAR=32%, 95% CI=−2%–64%), early age of PO initiation (AHR=3.08, 95%; CI= 1.26–
7.47; PAR=30%, 95% CI=2%–59%), using illicit POs to get high but not to self-medicate a health 
problem (AHR=4.83, 95% CI= 2.11–11.0; PAR=38%, 95% CI=12%–65%), and ever using PO 
non-orally most often (AHR=6.57, 95% CI=2.81–17.2; PAR=63%, 95% CI=31%–86%) were 
significant predictors.
Conclusion—This is one of the first prospective studies to test observations from previous 
cross-sectional and retrospective research on the relationship between illicit PO use and heroin 
initiation among young, initially non-opioid dependent PO users. The results provide insights into 
targets for the design of urgently needed prevention interventions.
Keywords
illicit pharmaceutical opioid use; heroin initiation; opioid dependence; time-to-event analysis; 
natural history study
1. INTRODUCTION
Over the past decade, the non-medical use of pharmaceutical opioids emerged as one of the 
fastest growing forms of drug abuse in the United States with young adults showing rates 
higher than other age groups (Johnston et al., 2010; Substance Abuse and Mental Health 
Services Administration (SAMHSA), 2010). Increases in illicit pharmaceutical opioid (PO) 
use resulted in escalating accidental overdose death rates (Paulozzi et al., 2006) and 
increasing prevalence of opioid abuse and dependence disorders (McCabe et al., 2008). Prior 
research with an Appalachian sample of illicit drug users demonstrated that PO use, in 
particular illicit use of OxyContin (pre-abuse deterrent formulation), was related to a high 
risk of transition to injection (Young and Havens 2011).
Growing evidence also suggests that illicit PO use has expanded pathways to heroin 
initiation and contributed to the heroin epidemic in the United States. Qualitative and cross-
sectional quantitative studies conducted in different regions of the country, including Ohio 
as early as 2002 (Siegal et al., 2003a), Washington (Peavy et al., 2012), California, New 
York and Pennsylvania (Lankenau et al., 2012; Mars et al., 2014), were among the first to 
describe a trend of illicit PO users becoming opioid dependent and transitioning to heroin 
use. Analysis of data from the U.S. National Survey of Drug Use and Health (NSDUH) 
indicated that between 2002–2004 and 2008–2010, heroin use increased substantially among 
non-medical users of pharmaceutical opioids but remained unchanged among non-users 
(Jones, 2013). Martins and colleagues (2015) also found a significant relationship between 
illicit PO use and heroin use in the years 2008–2011 NSDUH cohort, compared to the 2002–
2005 period. Another NSDUH-based study found that the incidence rate of heroin initiation 
was approximately 19 times greater among prior illicit PO users than among non-users 
(Muhuri et al., 2013). Data on drug overdose hospitalizations and mortality rates 
demonstrated significant increases in heroin-related overdoses and reductions in PO-related 
overdose rates over the past few years (Unick et al., 2013; Dasgupta et al., 2014; Lee et al., 
Carlson et al. Page 2









2014; Rudd et al., 2014). Similar trends were identified in Ohio, with overdose death data 
showing large increases in heroin-related deaths and leveling off of PO-related deaths in 
2012 (Massatti et al., 2014). In Ohio, like other areas of the country, these increases appear 
to be linked to implementation of stricter pharmaceutical opioid prescription policies and 
guidelines (Massatti et al., 2014) and the introduction of an abuse-deterrent formulation of 
extended-release oxycodone (ADF OxyContin; Cicero and Ellis, 2015).
Although there is mounting evidence of the “intertwined” epidemics of illicit PO and heroin 
use, there is a lack of prospective studies designed to identify the factors associated with 
heroin initiation among illicit PO users. This study reports the findings of a 36-month 
natural history study of young adult illicit PO users who, at baseline, were not opioid 
dependent and had no history of heroin use or illicit injection. We examine associations 
between selected predictors and time to first heroin use using a time-to-event analysis. 
Potential predictors were selected mostly based on prior retrospective research findings 
suggesting associations between heroin initiation and: PO dependence (e.g., Jones, 2013, 
2015; Lankenau et al., 2012; Mars et al., 2014); frequency of PO use (Jones, 2013, 2015; 
Muhuri et al., 2013; Cicero and Ellis, 2015); route of administration (ROA; McCabe et al., 
2007a; Kirsh et al., 2012; Young et al., 2010); non-medical use of OxyContin (high abuse 
liability; Hays, 2004; Ternes and O’Brien, 1990; Siegal et al., 2003a,b; Martins et al., 2009; 
Cicero and Ellis, 2015; Young and Havens, 2011); and the introduction of ADF OxyContin 
(Cicero and Ellis, 2015).
2. METHODS
2.1. Sample recruitment
Between April, 2009 and May, 2010, we recruited 383 eligible participants in the Columbus, 
Ohio, area using respondent-driven sampling (RDS; Heckathorn, 1997, 2002). We limited 
referrals to three eligible participants and compensated referrers $15 for each person 
presenting at the project office (Wang et al., 2005, 2007). Daniulaityte and colleagues 
(2012) provide more details on sample recruitment.
Located in Franklin County, with a population over one million, Columbus is the Ohio state 
capitol, with a population of 787,033 people, 61% of whom are white, 28% African 
American, and 11% of other ethnicity (U.S. Census Bureau, 2010). Like much of Ohio, the 
Columbus area has experienced dramatic increases in the PO/heroin epidemics that began 
fomenting as early as 2002 when OxyContin was first identified as a potential new risk 
factor for heroin initiation (Siegal et al, 2003a,b). In Franklin County, unintentional drug 
overdose deaths increased 41.7% from 139 in 2009 to 197 in 2013 (Ohio Department of 
Health, 2014). In 2013, heroin was present in 46.6% of overdose deaths and POs in 34.4% 
(Ohio Department of Health, 2014).
2.2. Eligibility
Eligibility criteria included: 1) age 18–23 years (to recruit those in emerging adulthood 
when the risk of drug and drug-related behaviors peaks (Arnett, 2000; Bachman et al., 
1996); 2) self-reporting non-medical PO use on five or more occasions in the previous 90 
days (to recruit active PO users); 3) expressing intentions to use illicit POs again (to capture 
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active PO users); 4) residence in the Columbus, OH, area; 5) identifying opioids s/he 
reported having used on a pill card similar to that used in the NSDUH (Caviness et al, 2006), 
but without drug names listed (to verify reported illicit PO use); 6) no lifetime opioid 
dependence as ascertained with the DSM-IV Checklist (Forman et al., 2004; Hudziak et al., 
1993); 7) no self-reported history of heroin use or history of drug injection as verified by 
visual inspection of arms for injection track marks; 8) no pending criminal charges (to 
minimize loss to follow-up); and 9) not involved in formal substance abuse treatment in the 
past 30 days (to avoid recruiting participants in active recovery who would be different from 
active users not wishing to stop drug use).
2.3. Data collection
Baseline and follow-up structured questionnaires (conducted every six months for 36 
months) were administered by trained interviewers in private offices following completion 
of an informed consent. Participants were compensated $50 for completing a 1.5–2.5 hour 
baseline interview. Compensation for follow-up interviews was $40 for briefer semi-annual 
interviews and $50 for longer, annual follow-up interviews. All protocols were approved by 
the Wright State University IRB.
The final 36-month follow-up interview was conducted in May 2013, and retention rates 
were excellent. Of the 383 participants interviewed at baseline, 89.8% returned at 6 months; 
88.5% at 12 months; 86.7% at 18 months, 83.3% at 24 months; 78.6% at 30 months; and 
73.4% at 36 months.
2.4. Outcome and predictors
The outcome in this time-to-event analysis was time from initiation of illicit PO use to 
heroin initiation. Age of initiation of illicit PO use was self-reported as a whole number, and 
initiation of heroin use was self-reported as using heroin for the first time since the most 
recent follow-up interview. The outcome was computed as the difference between the age at 
the first interview where heroin use was reported and the age of initiation of illicit PO use.
Frequency of illicit PO use was ascertained through an author-generated item previously 
employed (Carlson et al., 2005; Falck et al., 2005; Siegal et al., 1998): “During the past six 
months, how often did you use non-prescribed pain pills (e.g., Vicodin, Percocet)?” Seven 
response options ranged from “never/none” to “daily” and were collapsed to ≤ 1, about 2, 
and ≥ 3 days per week. The predictor, “frequency of pain pill use,” represents the maximum 
reported value since the baseline interview.
At baseline and follow-up interviews, lifetime use (yes/no) of other drugs (alcohol, 
marijuana, sedatives (“non-prescribed tranquilizers like Xanax, Ativan, Valium”), cocaine, 
non-prescribed stimulants (‘like Ritalin, Adderall, Concerta”), MDMA, and LSD were 
ascertained using the questions “Have you ever used [drug]?” and “Since your last 
interview, have you used [drug]?” Use of immediate-release oxycodone was ascertained via 
the question: “Have you ever (since your last interview) used Percocet, Percodan, Tylox, or 
other drugs containing immediate-release oxycodone?” Use of OxyContin was assessed by 
asking a similar question. Use of ADF OxyContin was added as a distinct question in 
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November, 2010, roughly coinciding with the availability of the reformulation in December, 
2010 (Cicero and Ellis, 2015).
Lifetime opioid dependence was assessed using the DSM-IV checklist (Forman et al., 2004; 
Hudziak et al., 1993). The computerized version of the Diagnostic Interview Schedule 
(CDIS) was used to ascertain lifetime dependence on other drugs, and lifetime psychiatric 
comorbidity (ASPD, depression, GAD, mania, or PTSD; Robins et al., 1999). The only 
drugs with greater than minimal prevalence of dependence for both those who did and did 
not transition to heroin were alcohol and marijuana. Thus, other drug dependence variables 
(sedatives, cocaine, stimulants, MDMA, LSD) were excluded as predictors.
Route of non-medical pharmaceutical opioid administration (ROA) was assessed with the 
question, “In the past 6 months, how did you most often use non-prescribed pain pills (e.g., 
Vicodin, Percocet)?” Responses included: “smoke,” “orally,” “sniff/snort,” “inject,” “other,” 
and “do not know/Refused.” Non-oral routes of administration were grouped together 
because only one participant reported an ROA other than “oral” or “sniff/snort.” The 
predictor used was “PO ever administered non-orally most often” (yes/no).
Other predictors were sex, employment (unemployed vs. part-time vs. full-time), post high-
school education (yes/no), age of PO initiation (considered both as a continuous version and 
dichotomized as age of initiation ≤ 15 years old), and reasons for illicit PO use (ever used 
“pain pills illicitly to get high”; and, ever used “pain pills illicitly to self-medicate a health 
problem”).
2.5. Statistical analysis of time to initiation of heroin use
Rate of transition to heroin use was computed as the number of participants who initiated 
heroin use before the end of our study divided by the number of person-years these 
participants were observed prior to heroin use, and then expressed as an annual percentage 
(rate per 100 persons per year). A 95% CI for the rate was computed using the OpenEpi free 
calculator (0penEpi, 2010).
Time to heroin initiation was analyzed using Cox regression (Cox, 1972), accounting for left 
truncation and right censoring. The hazard of transition to heroin use was modeled as a 
function of each predictor individually, and collectively using a multivariate model. 
Predictor effect sizes were quantified as hazard ratios (HR) and, in the multivariate model, 
adjusted hazard ratios (AHR). A predictor with HR or AHR > 1 is associated with shorter 
time to initiation. The non-proportional hazards assumption was checked (and met) for time-
invariant predictors (age of illicit PO initiation, early initiation of PO, and sex). The model 
was fit via SAS PROC PHREG (SAS Institute, 2010). All tests were two-sided and 
conducted at the α = 0.05 level.
To prevent biased HR estimates due to reverse causation (in which a predictor changes 
because of initiation of heroin use rather than vice versa), the predictor value associated with 
heroin initiation was the value at the previous interview. Almost everyone used alcohol and 
marijuana; therefore, they were excluded as predictors. Lifetime use of immediate-release 
oxycodone, use of OxyContin, and non-medical use of POs to get high were universal 
Carlson et al. Page 5









among heroin initiates and were excluded from the analyses (due to non-convergence of the 
algorithm). Multicollinearity among predictors was checked by computing variance inflation 
factors, all of which were low. Stepwise variable selection was employed to determine the 
final multivariate model; predictors with p < 0.05 were included in the final model, and 
adjusted hazard ratios (AHR) were estimated for each. Finally, for predictors in the final 
model, we computed the population attributable risk (PAR) = prevalence of risk factor 
among those who initiated heroin × (AHR-1)/AHR, which is an estimate of the reduction in 
heroin initiation that would occur if a particular risk factor was eliminated (Natarajan et al., 
2007).
Weighted estimates are often used in studies using RDS to sample from hard-to-reach 
populations of interest, particularly in cross-sectional surveillance studies where there is 
significant interest in external validity and making inferences to the population (Johnston 
and Sabin, 2010). We considered using weighted estimates in our analyses, but chose not to 
because our focus was on ensuring the internal validity of the study. In addition, a number of 
issues also made using weighted estimates impractical. Since our longitudinal cohort is a 
subset of the original RDS sample, referral chains are broken so that RDS weights cannot be 
properly created when using the RDS analysis tool RDSAT. Accurate network size 
information is also critical to the validity of RDS weighting in producing population 
estimates (Johnston, 2008; Johnston et al, 2008). However, the eligibility criteria for our 
study were comparatively restrictive to improve internal reliability and not completely 
revealed to participants to prevent individuals from lying to obtain study admission. As a 
result, our self-reported network sizes are likely not reflective of the target population. In 
addition, despite lengthy recruitment chains, our sample did not reach equilibrium for racial/
ethnic composition (Daniulaityte et al., 2012:26). Lack of equilibrium undermines the 
validity of applying RDS weights to race/ethnicity (Johnston, 2008; Johnston et al., 2008). 
The absence of equilibrium in terms of ethnic composition is most likely due to high 
homophily levels observed among Whites (.79) and African Americans (.80) (Daniulaityte 
et al., 2012), indicating that the two groups recruited almost exclusively from their own 
group, producing a “bottleneck” in the network and impacting the quality of RDS estimates 
(Goel and Salganik, 2009; Gile and Handcock, 2010). Finally, the ability of RDS weights to 
produce population estimates for parameters in complex analyses (for example, the adjusted 
hazard ratios we estimate) is questionable (Li, 2012), particularly for longitudinal analyses 
(Yan 2012). Despite these limitations, using RDS provided a practical and efficient means to 
recruit the sample.
3. RESULTS
About 50% of the sample were White (including Hispanic); among the 180 non-Whites, 
92.8% were African American, 2.2% were Asian or Pacific Islander, and 5% biracial. On 
average, Whites and non-Whites had been using POs non-medically for about four years at 
baseline, with a mean age of PO initiation of 16.6 years for Whites and 17.3 years for non-
Whites (Table 1). For further details regarding the baseline sample, see Carlson and 
colleagues (2014).
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3.1. Characteristics of individuals who initiated heroin use
Over 36 months, 27 (7.5%) participants initiated heroin use, and the rate was 2.8% per year 
(95% CI=1.9%–4.1%). All participants who transitioned to heroin use were white (including 
one Hispanic). About 56% of heroin initiates were male, and more than half had some post-
secondary education. Four (14.8%) heroin initiates reported that their most frequent route of 
heroin administration (during the first 6-month period they reported heroin initiation) was 
smoking, 11 (40.7%) reported sniff/snort, and 12 (44.4%) reported injection (data not 
shown).
Table 2 provides characteristics of heroin users and non-users at the most recent lagged 
follow-up interview. The mean number of years from first illicit PO use to heroin initiation 
was 6.2. All heroin initiates reported lifetime use of OxyContin, compared to only 46.3% of 
those who did not transition to heroin. The two groups did not differ in terms of immediate-
release oxycodone use. Only three (11%) heroin users reported ADF OxyContin use before 
heroin initiation. Non-oral route of PO administration was more commonly reported among 
those who transitioned to heroin use (74.1% versus 21.5%). Over 55% of heroin initiates 
became opioid dependent prior to using heroin, compared to 43.3% of non-heroin initiates. 
All the heroin users and about 93% of non-users had used pharmaceutical opioids non-
medically to “get high.” In contrast, use of POs to self-medicate a health problem was more 
commonly reported among non-heroin users than heroin initiates (89.0% vs. 51.9%). The 
two groups also differed in terms of frequency of PO; 63% of heroin initiates reported using 
PO ≥ 3 days per week, compared to 46% of non-heroin users.
3.2. Time-to-event analysis: unadjusted heart ratios (HRs)
Unadjusted HRs and 95% confidence intervals (CI) for all candidate predictors are shown in 
Table 3. Significant predictors of heroin initiation included three predictors related to PO 
use: developing lifetime opioid dependence (HR=2.74; 95% CI=1.27–6.08); having a higher 
lifetime maximum number of opioid dependence criteria (HR=1.37; 95% CI=1.11–1.68); 
and a higher maximum frequency of PO use (3–7 days per week vs. 1 day per week, 
HR=2.58; 95% CI=1.06–7.19; 3–7 days per week vs. 2 days per week, HR=2.87; 95% 
CI=1.06–9.98). Two age-related predictors were significant: age of initiation ≤ 15 years 
(HR=3.12; 95% CI=1.30–7.45); and younger age of initiation (as a continuous variable) 
(HR=0.69, 95% CI=0.54–0.89). Using POs to self-medicate a health problem (HR=0.18, 
95% CI=0.08–0.40) was significantly (negatively) related to heroin initiation. Ever reporting 
non-oral use of POs (HR=10.1; 95% CI=4.46–25.9); alcohol dependence (HR=2.16, 95% 
CI=1.01–4.76); and each of ever having used sedatives (HR=2.91, 95% CI=1.17–8.80), 
cocaine (HR=6.34, 95% CI=2.67–17.5), stimulants (HR=2.34, 95% CI=1.09–5.13), MDMA 
(HR=2.53, 95% CI=1.10–6.54), and LSD (HR=3.89, 95% CI=1.75–9.53) were also 
significant predictors.
3.3. Time-to-event analysis: Adjusted hazard ratios
In the final multivariate model (Table 4), predictors of heroin initiation included: lifetime 
PO dependence (AHR=2.39, 95% CI= 1.07–5.48); early age of PO initiation (age ≤ 15 
years) (AHR=3.08, 95%; CI= 1.26–7.47); never reporting PO use to self-medicate a health 
problem (AHR=4.83, 95% CI= 2.11–11.0); and ever reporting administering POs non-orally 
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most often (AHR=6.57, 95% CI=2.81–17.2). Maximum frequency of PO use, lifetime 
maximum number of PO dependence criteria, and lifetime PO dependence (yes/no) were 
almost interchangeable in the final model in terms of estimated AHRs for the other 
predictors and model fit, with greater frequency and more criteria each associated with 
shorter time to heroin initiation. Since frequency of PO use is related to the development of 
opioid disorder, this is not surprising. Of these three equivalent final models, we chose 
lifetime PO dependence because it was the predictor in which we were most interested.
The PARs were 63% (95% CI=31%–86%) for non-oral PO administration, 38% (95% 
CI=12%–65%) for never self-medicating (i.e., using only to get high), 32% (95% CI=−2%–
64%) for PO dependence, and 30% (95% CI=2%–59%) for early illicit PO initiation.
4. DISCUSSION
To our knowledge, this is the first prospective study to use a community-based sample to 
examine the relationship between illicit PO use and heroin initiation among young adults in 
the U.S. who, at baseline, were not opioid dependent and had no history of heroin use or any 
illicit drug injection. In addition, it is the first community-based study to provide an estimate 
of the rate of heroin initiation among young PO users as well as PAR estimates associated 
with significant predictors.
Over 36 months, among our sample of 362, 18–23 year olds, 27 (7.5%) participants initiated 
heroin use. Our findings suggest that the rate of transition to heroin initiation among initially 
non-opioid dependent PO users is 2.8% per year in a Midwest U.S. metropolitan area in the 
heart of the opioid epidemics.
Muhuri and colleagues (2013) reported rates of heroin initiation based on a 2009–2011 
cohort of lifetime illicit PO users and heroin use based on NSDUH data. However, these 
estimates are not truly comparable with our estimate. For instance, the NSDUH national 
sampling method and resulting sample characteristics differ substantially from ours. 
Nevertheless, in their study, the age group with the highest annual average rate (0.26%) is 
18–25 year olds, and the racial/ethnic group with the highest annual average rate (0.14%) is 
non-Hispanic Whites. Thus, our higher rate estimate (2.8%) reflects the age and race/ethnic 
group arguably at highest risk.
All of the 27 heroin initiates were White (including one Hispanic). Identifying the reasons 
for the racial/ethnic variation in the relationship between PO use and heroin initiation is 
important and challenging, particularly given that 47.2% of non-Whites became opioid 
dependent, yet none initiated heroin use (data not shown). We offer preliminary 
observations regarding why non-Whites did not transition to heroin use. Our RDS study 
(Daniulaityte et al, 2012) indicated high levels of in-group recruitment, indicating greater 
social distance between Whites and non-Whites; subcultural views on drug use practices 
may vary Whites and non-Whites. Among 180 non-Whites, only 14 (7.8%) used POs non-
orally most often prior to their last visit (data not shown), which was the most significant 
predictor among Whites who transitioned to heroin. Low levels of non-oral PO use among 
non-Whites may be related to a subcultural values regarding non-oral administration routes. 
When asked why there are comparatively lower levels of heroin use among non-Whites, a 
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treatment provider in Columbus, OH, (personal communication December 4, 2015) 
suggested that a long history of heroin use in African-American communities may have 
engendered negative views about heroin use among younger generations. Mars and 
colleagues (2014) identified similar racial/ethnic differences in terms of heroin initiation in 
ethnographic studies in Philadelphia and San Francisco. We agree with their call for further 
research to examine the effects of ethnicity, segregation, socio-economic status, and 
geography on heroin initiation risk. We also suggest that the potential impact of 
stigmatization of heroin use among non-Whites should be examined.
Among significant AHR predictors, ever administering PO non-orally (sniffing/snorting) 
most often before heroin initiation had the highest PAR estimate (63%). This finding is 
consistent with previous research indicating the significance of ROA in increasing the rate 
of drug absorption and speed of onset, and, thereby, its association with transition to 
dependence, regardless of drug (e.g., Gossop et al., 1994; Strang et al., 1992, 1998; Samaha 
and Robinson, 2005). The finding supports previous research that crossing the bridge from 
illicit oral PO administration to crushing POs and sniffing/snorting (or smoking, injecting) 
them indicates an intensifying relationship with the drug and “high” as well as the potential 
for drug-related problems (Kirsh et al., 2012; McCabe et al., 2007a; Young et al., 2010). As 
such, ROA is an important target for intervention among non-opioid dependent illicit PO 
users.
Our final model indicates that developing PO dependence is a significant predictor of heroin 
initiation (PAR=32%). The finding is consistent with previous cross-sectional retrospective 
research (Cicero et al., 2014; Lankenau et al., 2012; Mars et al. 2014; Peavy et al., 2012; 
Pollini et al., 2011; Siegal et al. 2003a,b). As some studies (e.g., Siegal et al., 2003a) 
propose, transition to PO dependence becomes increasingly costly over time, access to POs 
becomes more problematic, and heroin is a less-expensive, easily accessible alternative that 
largely markets itself. The field lacks an understanding of changes in social networks as 
non-dependent PO users transition to opioid dependence and engage with heroin using 
networks.
Illicit PO users who used the drug more frequently were also more likely to transition to 
heroin use. This finding is consistent with the fact that frequency of PO use is likely to be 
related to transition to opioid dependence. As such, reducing frequency of PO use is an 
important target for intervention to prevent transition to opioid dependence and potential 
risk for heroin initiation.
The PAR estimate (38%) for never having used illicit POs to “self-medicate a health 
problem” (i.e., in our study, only ever using “to get high”) was very similar to the PAR for 
opioid dependence (32%). This finding is consistent with McCabe and colleague‘s (2009, 
2013) hypothesis that use of POs for “self-treatment of pain” would be associated with 
fewer substance abuse problems, while use for recreational motives (“to get high” in our 
study) would result in greater negative effects. In our LCA of the baseline sample (Carlson 
et al., 2014), we reported that the classes with the greatest proportion of individuals who 
used POs only to self-medicate had the fewest negative characteristics associated with PO 
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use. The findings further support McCabe and colleagues‘ (2007a; 2009) point that motive 
for illicit PO use is an important variable that could inform intervention approaches.
The final significant predictor in the multivariate analysis was early age of PO initiation (≤ 
15 years) with the lowest PAR of 30%. Numerous studies have identified age of onset of 
drug use as a predictor of progression to problematic drug use (e.g., Kandel and Yamaguchi, 
1993 Hingson et al., 2006). Findings are consistent with McCabe and colleague‘s (2007b) 
study indicating that early age of illicit PO onset is associated with developing opioid 
dependence (placing users at higher risk of heroin initiation). Based on a NSDUH sample of 
U.S. adolescents, Cerdá and colleagues (2015) found that those initiating illicit PO use at 
ages 10–12 (followed by 13–15 year-olds) had the highest risk of heroin initiation, thus 
supporting our findings and confirming the importance of preventing early onset of illicit PO 
use.
All heroin initiates had used OxyContin, compared to just over 46% of those who did not 
initiate heroin use. This predictor could not be included in the analysis because when one 
group has no variation, the HR is not estimable. Nevertheless, our findings are consistent 
with previous studies indicating a relationship between OxyContin use and heroin use 
(Martins et al., 2009). We were among the first to report an emerging relationship between 
OxyContin use and heroin initiation in 2002 (Siegal et al., 2003a,b; Daniulaityte et al., 
2006). Importantly, Young and Havens (2011) reported that OxyContin use was associated 
with faster transition to injection among rural Appalachians in Kentucky.
The introduction of ADF OxyContin has been associated with increases in transition to 
heroin use (Cicero and Ellis, 2015). Use of ADF OxyContin was not a significant predictor 
of heroin initiation, although the unadjusted HR was fairly large in magnitude (HR=2.60). 
To examine the potential influence of the introduction of the abuse-deterrent formulation of 
OxyContin on heroin transition further, we calculated incidence rates before and after the 
availability of ADF OxyContin, using December 1, 2010 (Cicero and Ellis, 2015) as an 
approximate date for availability. In the pooled sample with all participants, the incidence 
rate was 2.8% (27 transitions in 950 person-years). From the start of the study through 
November 30, 2010, the incidence rate was 4.7% (13 transitions in 276 person-years). From 
December 1, 2010 to the end of the study, the incidence rate was 2.1% (14 transitions in 658 
person-years). Thus, the rate did change after the approximate date of availability of ADF 
OxyContin (December 2010), but not in the direction that would be expected.
4.1. Limitations
Our study was limited to 18–23 year-olds; results may be different for older or younger non-
dependent PO users. Our study was limited to a metropolitan area in the U.S.; however, 
Columbus, Ohio, is located in one of the “hot spots” of the opioid epidemics, and has been 
for over a decade (Siegal et al. 2003a). Predictors of heroin initiation among similar 
community-based samples may vary. In addition, the design excluded individuals who were 
pharmaceutical opioid dependent at baseline, thereby limiting the scope of our study. To 
make the sample as representative as possible, we used RDS. However, the sample may be 
biased by income level, education, employment, and other factors. In addition, the inability 
to adjust for RDS weighting is a limitation to the study. The recruited sample was young, 
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with some participants still financially dependent on their families, making assessment of 
socioeconomic status challenging. Additionally, since no non-white participants transitioned 
to heroin, it was not possible to adjust for race/ethnicity in the analysis. Thus, HRs and 
AHRs for predictors that differed greatly between racial/ethnic groups, in particular, non-
oral route of administration, may be biased. Finally, the findings are based on self-report, 
but there is substantial support for the validity and reliability of self-report data (Adair et al., 
1995; Darke, 1998; Passik et al., 2006).
4.2. Conclusion
Many areas of the U.S. have experienced over a decade of the evolution of the 
pharmaceutical opioid and heroin epidemics. The synergism between these epidemics is 
unmistakable and ever-changing. It is, in part, motivated by marketing of pharmaceutical 
opioids, changes in prescribing practices, and the availability of heroin that fills the gap 
when illicit pharmaceutical opioids are difficult to obtain as tolerance to opioids increases, 
all in the context of apparent growing demand for central nervous system depressants (Unick 
et al., 2013). The opioid epidemics are escalating public health crises that require a public 
health response proportionate in scale. Our results suggest that preventing transition to non-
oral pharmaceutical opioid use, preventing transition to opioid dependence (by reducing/
maintaining (or eliminating) frequency of PO use), and educating PO users about the risks 
involved in reasons for use among those non-opioid dependent are important intervention 
targets. Finally, prevention of early age of illicit PO initiation is also vital (Cerdá et al., 
2015).
Our prospective findings from a community-based sample provide insights into key 
dimensions for the design and testing of urgently needed interventions that require 
additional investment of resources. A harm-reduction intervention approach might include 
testing of office-based, or peer leader-based, interventions to prevent transition to opioid 
dependence among non-opioid dependent PO users as well as interventions for opioid 
dependent users who have not initiated heroin use. Such interventions could also include 
overdose prevention and prevention of blood-borne disease transmission.
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• Identify heroin initiation predictors among pharmaceutical opioid (PO) users
• Over 36 months, 7.5% (27) of 362 participants initiated heroin use
• Predictors: PO dependence; early age PO use; using PO to get high; non-oral PO 
use
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Table 3
Unadjusted associations between lagged predictors and hazard of transition to heroin
Unadjusted
Predictor HR 95% CI p-value
PO dependence (lifetime) 2.74 (1.27, 6.08) 0.0109
PO dependence criteria (lifetime max) 1.37 (1.11, 1.68) 0.0037
Frequency of pain pill use (maximum since 6 months before baseline) -- -- 0.0409
 3–7 days/week vs. ≤ 1 day/week 2.58 (1.06, 7.19) 0.0362
 About 2 days/week vs. ≤ 1 day/week 0.90 (0.23, 3.16) 0.8696
 3–7 days/week vs. 2 days/week 2.87 (1.06, 9.98) 0.0377
Early initiation (age of initiation ≤ 15 years) 3.12 (1.30, 7.45) 0.0111
Age of initiation of use of POs (years) 0.69 (0.54, 0.89) 0.0043
Sex (male vs. female) 1.06 (0.49, 2.32) 0.8805
Employment -- -- 0.0751
 Fulltime vs. unemployed 1.03 (0.32, 3.30) 0.9617
 Part-time vs. unemployed 2.46 (0.99, 6.93) 0.0519
 Fulltime vs. Part-time 0.42 (0.15, 1.03) 0.0587
Some college (vs. ≤ HS/GED) 1.42 (0.66, 3.09) 0.3703
ADF OxyContin (lifetime) 2.60 (0.61, 7.60) 0.1712
Used POs to self-medicate a health problem (since 6 months before baseline) 0.18 (0.08, 0.40) <0.0001
POs ever administered non-orally most often (since 6 months before baseline) 10. 1 (4.46, 25.9) <0.0001
Alcohol dependence (lifetime) 2.16 (1.01, 4.76) 0.0482
Marijuana dependence (lifetime) 0.74 (0.32, 1.63) 0.4628
Sedative use (lifetime) 2.91 (1.17, 8.80) 0.0201
Cocaine use (lifetime) 6.34 (2.67, 17.5) <0.0001
Stimulant use (lifetime) 2.34 (1.09, 5.13) 0.0289
MDMA/Ecstasy use (lifetime) 2.53 (1.10, 6.54) 0.0277
LSD use (lifetime) 3.89 (1.75, 9.53) 0.0007
Psychiatric comorbidity (lifetime) 1.22 (0.57, 2.77) 0.6204

















































































































































































































































































































Drug Alcohol Depend. Author manuscript; available in PMC 2017 March 01.
